Advertisement
U.S. markets close in 4 hours 5 minutes
  • S&P 500

    5,254.75
    +6.26 (+0.12%)
     
  • Dow 30

    39,781.64
    +21.56 (+0.05%)
     
  • Nasdaq

    16,404.89
    +5.37 (+0.03%)
     
  • Russell 2000

    2,131.81
    +17.46 (+0.83%)
     
  • Crude Oil

    82.70
    +1.35 (+1.66%)
     
  • Gold

    2,234.40
    +21.70 (+0.98%)
     
  • Silver

    24.92
    +0.17 (+0.68%)
     
  • EUR/USD

    1.0803
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.1870
    -0.0090 (-0.21%)
     
  • GBP/USD

    1.2628
    -0.0010 (-0.08%)
     
  • USD/JPY

    151.3280
    +0.0820 (+0.05%)
     
  • Bitcoin USD

    71,373.52
    +2,396.14 (+3.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,964.25
    +32.27 (+0.41%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Alnylam presents new pre-clinical data on RNAi therapeutics

Alnylam Pharmaceuticals announced that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemoglobinopathies at the 54th American Society of Hematology Annual Meeting being held December 8-11, 2012 in Atlanta. Alnylam scientists presented data showing that ALN-TMP, an RNAi therapeutic targeting Tmprss6, leads to disease modifying effects, including a correction in globin gene expression, in a model of ß-thalassemia. These studies were conducted in collaboration with Boston Children’s Hospital. Alnylam’s program in hemoglobinopathies comprises part of its ‘Alnylam 5x15™’ product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced stages, by the end of 2015.

Advertisement